

Metastatic Prostate Cancer With PCWG3 Review

65 sites

Bone scintigraphy, CT

PCWG3 and RECIST 1.1

Challenge

Radiographic progression-free survival in metastatic prostate cancer depends on disciplined application of the PCWG3 2+2 rule, under which new bone lesions must be confirmed on a subsequent scan before progression is declared. Across 65 sites, this rule was being applied inconsistently, with the flare phenomenon and unconfirmed lesions variously counted or disregarded. Such inconsistency placed the accuracy of the trial's rPFS endpoint—and the integrity of event dating—squarely at risk.

Our Solution

Intrinsic Imaging embedded PCWG3 decision logic directly into the central reading workflow, so that no newly identified bone lesion could be scored as progression without confirmation on a later examination. Central readers assessed bone scintigraphy alongside CT under RECIST 1.1 for soft-tissue disease, with the confirmatory requirement enforced systematically rather than left to individual judgment. Every progression event was dated according to a uniform convention, producing a coherent and defensible rPFS dataset.

Results

- Central assessment of 2900+ bone scans
- Consistent rPFS event dating
- No outstanding progression-logic queries at database lock

Read the full study online: <https://www.intrinsicimaging.com/case-studies/oncology-prostate>

About Intrinsic Imaging, LLC

Intrinsic Imaging is a full-service medical imaging core lab providing comprehensive services in support of Phase I-IV clinical trials and Class I, II, III medical device trials. Intrinsic Imaging is also a world leader in conducting Artificial Intelligence studies. With its team of more than 750 board-certified and fellowship-trained physicians, Intrinsic Imaging's team has sub-specialization in all therapeutic areas, including Cardiovascular, Central Nervous System, Gastroenterology, Musculoskeletal, Oncology and Ophthalmology. Certified by the British Standards Institution (BSI), Intrinsic Imaging is the only company in the world to hold five ISO certifications specifically for providing imaging core lab services on clinical trials. For more information, please visit www.IntrinsicImaging.com.

Contact:

Intrinsic Imaging, LLC
580 Main St., Suite 210
Bolton, MA, 01740, USA
+1 978-616-4650
Contact@IntrinsicImaging.com